Download PDFPDF

443 Open-label, phase 2 study to assess the safety of mogamulizumab at 2 mg/kg Q4W maintenance dosing in patients with relapsed/refractory MF/SS subtypes of CTCL
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address